Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes

Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in patients with type 1 diabetes. Materials and Methods...

Full description

Bibliographic Details
Main Authors: Koki Chiba, Hiroshi Nomoto, Akinobu Nakamura, Kyu Yong Cho, Kumiko Yamashita, Yui Shibayama, Aika Miya, Hiraku Kameda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Journal of Diabetes Investigation
Subjects:
Glucose variability
Sodium–glucose cotransporter 2 inhibitor
Type 1 diabetes
Online Access:https://doi.org/10.1111/jdi.13335

Internet

https://doi.org/10.1111/jdi.13335

Similar Items